34966-41-1

Basic information

• Product Name: Cartazolate
• Synonyms: Cartazolate;4-Butylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester;SQ-65396
• CAS NO: 34966-41-1
• Molecular Formula: C₁₅H₂₂N₄O₂
• Molecular Weight: 290.36
• Product Categories: API
• Mol File: 34966-41-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 420.8°Cat760mmHg
• Flash Point: 208.3°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 2.74E-07mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: Cartazolate(CAS DataBase Reference)
• NIST Chemistry Reference: Cartazolate(34966-41-1)
• EPA Substance Registry System: Cartazolate(34966-41-1)

Safety Data

• Hazardous Substances Data: 34966-41-1(Hazardous Substances Data)

Usage

Uses

Antidepressant.

InChI:InChI=1/C15H22N4O2/c1-4-7-8-16-13-11-10-18-19(5-2)14(11)17-9-12(13)15(20)21-6-3/h9-10H,4-8H2,1-3H3,(H,16,17)

Upstream product

• 30720-25-3 ethyl 4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 109-73-9 N-butylamine 
• 26823-99-4 [[(1-ethyl-5-pyrazolyl)amino]methylene]malonic acid diethyl ester 
• 3528-58-3 5-Amino-1-ethylpyrazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Relevant articles and documents

METHODS AND TOOLS FOR THE THERAPY OF NEURODEGENERATIVE PATHOLOGIES

The present invention concerns compositions and methods for the treatment of neurodegenerative diseases in which the cognitive functions are altered, such as observed in Alzheimer's disease. More particularly, the invention presents a strategy for human clinical monitoring of the activity and/or effectiveness of neuroprotective treatments, based on biochemical assay of certain platelet parameters, and thus can be done by blood sampling. The invention also concerns methods, tools, constructions and compositions suitable for implementing these strategies

Molecular target of neurotoxicity

The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further concerns the compounds, genes, cells, plasmids or compositions useful for implementing the hereinabove methods. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or experimental target.

Treatment of shock

The invention relates to a class of imidazoles substituted by cycloalkyl or cycloalkenyl which have pharmacological properties making them useful in medicine, in particular in the prophylaxis and treatment of thrombo-embolic disorders, and also of shock and angina pectoris.